Phathom Pharmaceuticals, Inc. (PHAT) Stock Forecast
Data as of Aug 2, 2026Healthcare · Current price $8.69 (-2.99%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 27, 2026 | Jenna Davidner | Barclays | $18.00 | +107.3% |
| Feb 26, 2026 | Annabel Samimy | Stifel Nicolaus | $28.00 | +222.4% |
| Dec 11, 2025 | Martin Auster | Raymond James | $28.00 | +222.4% |
| Dec 8, 2025 | Jenna Davidner | Barclays | $16.00 | +84.2% |
| Oct 31, 2025 | Chase Knickerbocker | Craig-Hallum | $22.00 | +153.3% |
| Oct 30, 2025 | Yatin Suneja | Guggenheim | $20.00 | +130.3% |
| Aug 8, 2024 | Paul Choi | Goldman Sachs | $12.00 | +38.2% |
| Jul 19, 2024 | Matthew Caufield | H.C. Wainwright | $28.00 | +222.4% |
| May 2, 2024 | Annabel Samimy | Stifel Nicolaus | $24.00 | +176.3% |
| Jan 5, 2024 | Joseph Stringer | Needham | $26.00 | +199.4% |
Top Analysts Covering PHAT
PHAT vs Sector & Market
| Metric | PHAT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 6 | 8 | 19 |
| Target Upside | +153.3% | +16316.0% | +17.1% |
| P/E Ratio | -3.73 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $326M | $332M | $335M | 7 |
| 2027-03-31 | $102M | $105M | $109M | 3 |
| 2027-06-30 | $115M | $119M | $123M | 3 |
| 2027-09-30 | $130M | $135M | $140M | 3 |
| 2027-12-31 | $152M | $157M | $163M | 3 |
| 2028-03-31 | $140M | $145M | $150M | 2 |
| 2028-06-30 | $161M | $167M | $173M | 2 |
| 2028-09-30 | $186M | $193M | $200M | 2 |
| 2028-12-31 | $214M | $222M | $230M | 2 |
| 2029-12-31 | $857M | $892M | $929M | 7 |
| 2030-12-31 | $977M | $1.02B | $1.06B | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-0.30 | $-0.28 | $-0.27 | 3 |
| 2027-03-31 | $0.13 | $0.14 | $0.15 | 1 |
| 2027-06-30 | $0.25 | $0.26 | $0.27 | 1 |
| 2027-09-30 | $0.38 | $0.40 | $0.42 | 1 |
| 2027-12-31 | $0.55 | $0.58 | $0.61 | 1 |
| 2028-03-31 | $0.41 | $0.43 | $0.45 | 1 |
| 2028-06-30 | $0.60 | $0.63 | $0.66 | 1 |
| 2028-09-30 | $0.78 | $0.82 | $0.86 | 1 |
| 2028-12-31 | $0.99 | $1.04 | $1.09 | 1 |
| 2029-12-31 | $3.92 | $4.13 | $4.35 | 4 |
| 2030-12-31 | $4.68 | $4.93 | $5.20 | 2 |
Frequently Asked Questions
What is the analyst consensus for PHAT?
The consensus among 6 analysts covering Phathom Pharmaceuticals, Inc. (PHAT) is Buy with an average price target of $24.67.
What is the highest price target for PHAT?
The highest price target for PHAT is $28.00, set by Annabel Samimy at Stifel Nicolaus on 2026-02-26.
What is the lowest price target for PHAT?
The lowest price target for PHAT is $12.00, set by Paul Choi at Goldman Sachs on 2024-08-08.
How many analysts cover PHAT?
6 analysts have issued ratings for Phathom Pharmaceuticals, Inc. in the past 12 months.
Is PHAT a buy or sell right now?
Based on 6 analyst ratings, PHAT has a consensus rating of Buy (2.00/5) with a +153.3% upside to the consensus target of $24.67.
What are the earnings estimates for PHAT?
Analysts estimate PHAT will report EPS of $-0.28 for the period ending 2026-12-31, with revenue estimated at $332M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.